Your CBD Store and Small Business Owners Call on Governor Abbott to Veto SB 3, Citing Devastating Economic Consequences
Sunmed™ | Your CBD Store® urges Texas Governor Greg Abbott to Veto Senate Bill 3
AUSTIN, Texas, June 9, 2025 /PRNewswire/ -- Sunmed™ | Your CBD Store®, along with its small business hemp retailers across the state, are urging Governor Greg Abbott to veto Senate Bill 3 (SB 3) in account of depriving law-abiding small businesses the opportunity to offer Texans wellness and therapeutic products that foster the Texas economy.
Unless Governor Abbott issues a veto against it, SB 3 will ban most hemp-derived cannabinoid products currently sold at over 7,500 licensed retail establishments throughout Texas. Sunmed | Your CBD Stores are owned by independent small businesses that rely on the sale of legal and wellness hemp-derived cannabinoid products to make a living and support their families.
Ralph Paul, who owns a Sunmed | Your CBD Store in Keller, Texas, warns:
"If SB 3 is signed into law, I'll have no choice but to shut down my businesses. This isn't just about product bans, it's about laying off employees, defaulting on leases, and losing everything we've built. We operate legally and transparently under the Texas Hemp Program. We don't deserve to be collateral damage in a political agenda."
Across the state, retailers are bracing for closures. Gary Brandt, owner of a Sunmed | Your CBD Store in Lakeway, Texas, adds:
"I've invested my savings, hired local staff, and served customers who depend on our wellness products. This bill doesn't just hurt businesses, it devastates families, communities, and the state's fiscal health. We're urging Governor Abbott to veto SB 3 and stand with small businesses."
According to the 2025 Economic Impact of Hemp Cannabinoid Processing and Manufacturing on Texas report by Whitney Economics, the hemp-derived cannabinoid industry is a cornerstone of the Texas economy:
53,300 Texans employed
$2.1 billion in wages paid
$5.5 billion in revenue generated
$267 million in retail sales tax contributed
$10–10.5 billion total economic impact
The Whitney report underscores that this industry's influence extends beyond storefronts and into rural farming, supply chains, distribution, and manufacturing. Over 8,500 total licenses, spanning retail, wholesale, and manufacturing, will be rendered obsolete.
Sunmed | Your CBD Store and its affiliate network support responsible regulation and consumer safety. However, SB 3 amounts to a prohibition and wipes out a thriving, tax-contributing industry that operates under a clear legal framework.
Call to ActionWe urge all Texans to oppose SB 3. Contact Governor Abbott and request that he veto this harmful legislation:
Call Governor Abbott: (512) 463-2000
Email the Governor: Contact Form
Sign the Texas Hemp Business Council Petition: Sign Petition
Sign the U.S. Hemp Roundtable Petition: Sign Petition
Sunmed stands with small businesses and the Texas communities they serve. We believe in protecting consumer access to safe, effective hemp products and supporting the local entrepreneurs who provide them. Join us in defending our industry, our economy, and our right to choose.
Contact Patrick ShatzerSunmed l Your CBD Storecustomersupport@getsunmed.com
About Sunmed™ | Your CBD Store® Sunmed | Your CBD Store, an affiliate of Sunflora, Inc., is the largest hemp retailer in the United States and the exclusive home of award-winning, hemp-derived Sunmed products. With 260+ nationwide locations across 39 states, the brand offers a premium in-store customer experience with access to 150+ nonpharmaceutical wellness formulas, including clinically proven sleep gummies, pain relief topicals, USDA-organic oil tinctures, and CBD for pets. Through in-store education, community involvement, and groundbreaking clinical research, Sunmed strives to empower modern wellness and enhance people's lives with natural science-backed products. Learn more at getsunmed.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/sunmed--your-cbd-store-and-small-business-owners-call-on-governor-abbott-to-veto-sb-3-citing-devastating-economic-consequences-302476750.html
SOURCE Sunmed
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
17 minutes ago
- Yahoo
Argo Named to Fast Company's 2025 World Changing Ideas List for Smart Routing™ Transit Platform
Vertically integrated transit solution recognized for transforming urban mobility and creating more equitable, sustainable cities TORONTO, June 11, 2025 /CNW/ - Argo Corporation (TSXV: ARGH) (OTCQX: ARGHF) ("Argo" or the "Company"), a leader in next-generation transit solutions, announced today that it was named a winner of Fast Company's 2025 World Changing Ideas Awards. This annual recognition honours bold and transformative efforts that tackle the world's most pressing challenges. Argo was recognized for its Smart Routing™ transit platform that aims to revolutionize how cities move people while addressing critical climate, equity, and accessibility challenges. Fast Company selected Argo as a winner from over 1500 initiatives worldwide, highlighting the Company's innovative approach to solving one of urbanization's greatest challenges: providing effective mobility for billions of people in rapidly growing cities while reducing emissions and improving quality of life. "The World Changing Ideas Awards have always been about showcasing the art of the possible," says Fast Company editor-in-chief Brendan Vaughan. "We're proud to recognize the organizations and leaders that are making meaningful progress on the biggest issues of our time." "We launched Argo one year ago today with a vision to solve one of the world's most urgent challenges: modernizing public transit so it's as convenient as driving, but accessible to everyone," said Praveen Arichandran, CEO and co-founder of Argo. "We're proud to be showcasing Canadian innovation on a global stage, starting in the town of Bradford West Gwillimbury and soon expanding to Brampton. This recognition by Fast Company affirms our belief that the next generation of globally ambitious companies can be built right here in Ontario." In conjunction with this award, Arichandran was also named to Fast Company's Impact Council, a collective of the most innovative leaders in business. About Fast CompanyFast Company is the only media brand fully dedicated to the vital intersection of business, innovation, and design, engaging the most influential leaders, companies, and thinkers on the future of business. Headquartered in New York City, Fast Company is published by Mansueto Ventures LLC, along with our sister publication Inc., and can be found online at About ArgoFounded in June 2024, Argo delivers the world's first fully vertically integrated transit system, combining proprietary Argo X1 electric vehicles, Smart Routing™ technology, and comprehensive operational management in a single end-to-end solution. By integrating every aspect of the transit experience, Argo enables municipalities to enhance their existing transit networks with dynamically optimized services that aim to deliver substantially better efficiency, coverage, and rider satisfaction, all while maintaining standard public transit pricing. The company launched Argo School in September 2024 and began its first municipal deployment in Bradford West Gwillimbury in early 2025. Learn more at Praveen Arichandran, CEOArgo Corporation(800) 575-7051 Forward-Looking InformationThis news release includes certain forward-looking statements as well as management's objectives, strategies, beliefs and intentions. Forward-looking statements are frequently identified by such words as "may", "will", "plan", "expect", "anticipate", "estimate", "intend" and similar words referring to future events and results. Forward-looking statements are based on the current opinions and expectations of management. All forward-looking information is inherently uncertain and subject to a variety of assumptions, risks and uncertainties, as described in more detail in the Company's securities filings available at Actual events or results may differ materially from those projected in the forward-looking statements and we caution against placing undue reliance thereon. We assume no obligation to revise or update these forward-looking statements except as required by applicable law. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. SOURCE ARGO CORPORATION View original content to download multimedia: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
32 minutes ago
- Yahoo
Mesoblast Maintains Momentum With FDA on Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure and Label Extension for Ryoncil® in Adults With GvHD
NEW YORK, June 11, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on continued momentum with United States Food and Drug Administration (FDA) regarding both accelerated approval pathway for Revascor® (rexlemestrocel-L) in the treatment of patients with ischemic chronic heart failure with reduced ejection fraction (HFrEF) and inflammation, and label extension for Ryoncil® (remestemcel-L-rknd) in adults with steroid refractory acute graft versus host disease (SR-aGvHD). In the first week of June, Mesoblast held a Type B meeting with FDA under its Regenerative Medicines Advanced Therapy (RMAT) designation for REVASCOR to discuss components of a potential filing for a Biologics License Application (BLA). There was general alignment on items regarding chemistry, manufacturing & controls (CMC), potency assays for commercial product release, and proposed design and primary endpoint for the confirmatory trial post-approval. The Company will await the final minutes from FDA in order to provide detailed feedback and timelines for potential filing. In early July, Mesoblast has an upcoming meeting with FDA to discuss a pivotal trial of Ryoncil® in adults with SR-aGvHD. This trial will be conducted with the NIH-funded Bone Marrow Transplant Clinical Trials Network (BMT-CTN), the objective being to extend the product's label from children to adults with SR-aGvHD. Ryoncil® is the first and only mesenchymal stromal cell product approved by the FDA for any indication. Ryoncil® became commercially available for purchase in the United States on March 28, 2025, within one quarter of receiving FDA approval to treat children with SR-aGvHD. More than 20 transplant centers will have been onboarded by the end of the quarter, exceeding the company's expectations at product launch. Mesoblast has continued to expand coverage for Ryoncil® to over 220 million US lives insured by commercial and government payers. To date, 37 of the 51 States provide fee-for-service Medicaid coverage for Ryoncil® through Orphan Drug Lists or medical exception / prior authorization (PA) process. The remainder will come online July 1, 2025, with mandatory coverage for all 24 million lives. 'We are very pleased with the momentum of interactions with FDA on both our cardiac and GvHD programs,' said Mesoblast Chief Executive Dr. Silviu Itescu. 'We are also encouraged by the strength of the of the Ryoncil® commercial launch, the rate of hospital onboarding, physician adoption, and payor coverage exceeding our expectations in the ten weeks since commercial launch. We will be providing an update on sales of Ryoncil® in our quarterly activities report at the end of next month.' About Mesoblast Mesoblast (the Company) is a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The therapies from the Company's proprietary mesenchymal lineage cell therapy technology platform respond to severe inflammation by releasing anti-inflammatory factors that counter and modulate multiple effector arms of the immune system, resulting in significant reduction of the damaging inflammatory process. Mesoblast's RYONCIL® (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months and older is the first FDA approved mesenchymal stromal cell (MSC) therapy. Please see the full Prescribing Information at Mesoblast is committed to developing additional cell therapies for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. RYONCIL is being developed for additional inflammatory diseases including SR-aGvHD in adults and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for heart failure and chronic low back pain. The Company has established commercial partnerships in Japan, Europe and China. About Mesoblast intellectual property: Mesoblast has a strong and extensive global intellectual property portfolio, with over 1,000 granted patents or patent applications covering mesenchymal stromal cell compositions of matter, methods of manufacturing and indications. These granted patents and patent applications are expected to provide commercial protection extending through to at least 2041 in major markets. About Mesoblast manufacturing: The Company's proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. These cell therapies, with defined pharmaceutical release criteria, are planned to be readily available to patients worldwide. Mesoblast has locations in Australia, the United States and Singapore and is listed on the Australian Securities Exchange (MSB) and on the Nasdaq (MESO). For more information, please see LinkedIn: Mesoblast Limited and X: @Mesoblast Forward-Looking StatementsThis press release includes forward-looking statements that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements should not be read as a guarantee of future performance or results, and actual results may differ from the results anticipated in these forward-looking statements, and the differences may be material and adverse. Forward-looking statements include, but are not limited to, statements about: the initiation, timing, progress and results of Mesoblast's preclinical and clinical studies, and Mesoblast's research and development programs; Mesoblast's ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; Mesoblast's ability to advance its manufacturing capabilities; the timing or likelihood of regulatory filings and approvals, manufacturing activities and product marketing activities, if any; the commercialization of Mesoblast's RYONCIL for pediatric SR-aGVHD and any other product candidates, if approved; regulatory or public perceptions and market acceptance surrounding the use of stem-cell based therapies; the potential for Mesoblast's product candidates, if any are approved, to be withdrawn from the market due to patient adverse events or deaths; the potential benefits of strategic collaboration agreements and Mesoblast's ability to enter into and maintain established strategic collaborations; Mesoblast's ability to establish and maintain intellectual property on its product candidates and Mesoblast's ability to successfully defend these in cases of alleged infringement; the scope of protection Mesoblast is able to establish and maintain for intellectual property rights covering its product candidates and technology; estimates of Mesoblast's expenses, future revenues, capital requirements and its needs for additional financing; Mesoblast's financial performance; developments relating to Mesoblast's competitors and industry; and the pricing and reimbursement of Mesoblast's product candidates, if approved. You should read this press release together with our risk factors, in our most recently filed reports with the SEC or on our website. Uncertainties and risks that may cause Mesoblast's actual results, performance or achievements to be materially different from those which may be expressed or implied by such statements, and accordingly, you should not place undue reliance on these forward-looking statements. We do not undertake any obligations to publicly update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise. Release authorized by the Chief Executive. For more information, please contact:Paul Hughes T: +61 3 9639 6036 Allison Worldwide Emma Neal T: +1 603 545 4843 E: BlueDot Media Steve Dabkowski T: +61 419 880 486 E: steve@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
‘100% of my products will be gone' local CBD and hemp store speaks out against Texas Senate Bill 3
SAN ANGELO, Texas (Concho Valley Homepage) — Texas Senate Bill 3, the bill aiming to ban THC products statewide, is stirring up strong emotions on both sides of the debate. Opponents of the bill say this will have a negative impact, while supporters say this is necessary to protect our most vulnerable populations. 'It is a scourge upon our young people to hook them on drugs forever… This was not controversial for the legislature; they passed it overwhelmingly, and we have to ban it,' Lt. Governor Dan Patrick said. Lt. Governor Dan Patrick is leading the charge, calling this bill a critical defense against what he describes as a public threat. He says the state of Texas has seen a drastic increase in the number of shops that sell these products. Texas THC ban: Lt. Gov. Patrick warns of youth health risks 'There are 8,000 or more smoke and vape shops that have opened in Texas in just the last 3-4 years,' Patrick said. Allen Kirk with Full Spectrum CBD says he disagrees with the legislature and finds this bill disheartening. 'San Angelo has blessed us with business, and we have helped a lot of people…and it is very disheartening that I have put blood, sweat and tears and now I'm going to be closed, because we have our legislature that does not understand the benefits of our products,' Kirk said. At Full Spectrum CBD, Kirk says he mainly serves people 35 years or older and a large population of veterans. Over the years, he has created a business that has had people wanting to come back. He says he is saddened by the thought of no longer being available to offer his customers reliable products. Gov. Abbott declines to say if he will sign THC ban 'What I'm really sad about is my clients. My older people are not going to get the stuff they need… the veterans who are just getting shut out again and not getting the proper help they need as far as PTSD and their pains…' Kirk said. If Senate Bill 3 passes, Kirk says his entire livelihood would be gone. 'When you grow hemp and you extract CBD, you are always going to have a trace amount of THC in it; you cannot grow it without THC. This is a total ban on THC, which basically means 100% of my products will be gone…there is not one product in here that I will be able to sell if this goes through,' Kirk said. He says Lt. Gov. Patrick was set on this path to ban THC because of people who did not follow the law and managed to sell products that contain THC above the legal limit. His store, Full Spectrum CBD, is not the kind of store Lt. Gov. Patrick should be after. Lt. Gov. Dan Patrick holds press conference following legislative session 'The unfortunate part about it is that in the middle of your agenda of getting rid of bad actors…I'm collateral damage,' Kirk said. Currently this bill awaits action from Texas Governor Greg Abbott. Until a decision is made, supporters and opponents of the bill are left to wonder what the future holds for legal hemp and CBD businesses. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
